Tesamorelin 5mg
Growth hormone-releasing factor analogue — 5mg starter vial for research protocols.
Key Benefits
FDA-approved mechanism showing 15–18% VAT reduction in clinical trials
stimulates natural pulsatile GH release without suppressing the hypothalamic-pituitary axis
reduces visceral fat while preserving lean muscle mass
emerging research shows improvements in executive function and memory via IGF-1 signaling
Active Signaling Pathway
Investigated Pathways
Proposed Mechanism
Tesamorelin is a stabilized analog of endogenous GHRH with a trans-3-hexenoic acid group attached to the N-terminus, which protects it from dipeptidyl peptidase IV (DPP-IV) degradation and extends its half-life to 26–38 minutes. It binds to GHRH receptors on pituitary somatotrophs, triggering cAMP-mediated GH synthesis and pulsatile release. The resulting GH elevation stimulates hepatic IGF-1 production, which mediates the lipolytic effects on visceral fat.
Research Highlights
- FDA-approved (2010) for HIV-associated lipodystrophy — one of the most rigorously studied GHRH analogs
- Phase III trials showed 15–18% reduction in visceral adipose tissue (VAT) over 26 weeks
- Demonstrated improvements in cognitive function (executive function, memory) in adults with mild cognitive impairment
- Unlike direct GH, Tesamorelin preserves the natural GH feedback loop via somatostatin — no axis suppression
Human observational or open-label study data exists. Controlled trial data may be limited. Not a treatment recommendation.
For laboratory research only
All Research Systems →Human Body
Research begins at the whole-organism level — studying systemic metabolic markers, energy expenditure, and physiological response to peptide intervention.
For laboratory research and educational purposes only.
Human Body
Research begins at the whole-organism level — studying systemic metabolic markers, energy expenditure, and physiological response to peptide intervention.
For laboratory research and educational purposes only.
For research use only — not for human consumption. No treatment claims.
Full Research Hub →How long will one vial last?
Based on standard research protocols, here's exactly what to expect from a single 5mg vial — and when to plan your next order.
Vial supply estimate is based on standard research protocol volumes. Actual duration will vary based on your specific protocol design.
Scientific Background
Mechanism of Action
Tesamorelin is a stabilized analog of endogenous GHRH with a trans-3-hexenoic acid group attached to the N-terminus, which protects it from dipeptidyl peptidase IV (DPP-IV) degradation and extends its half-life to 26–38 minutes. It binds to GHRH receptors on pituitary somatotrophs, triggering cAMP-mediated GH synthesis and pulsatile release. The resulting GH elevation stimulates hepatic IGF-1 production, which mediates the lipolytic effects on visceral fat.
Clinical Context
Tesamorelin has the strongest clinical evidence base of any GHRH analog, with multiple Phase III trials and FDA approval. Its visceral fat reduction effects are well-documented, and emerging research suggests cognitive benefits via IGF-1 signaling in the brain. The 10mg vial allows for extended protocols without frequent reordering.
Research Highlights
- FDA-approved (2010) for HIV-associated lipodystrophy — one of the most rigorously studied GHRH analogs
- Phase III trials showed 15–18% reduction in visceral adipose tissue (VAT) over 26 weeks
- Demonstrated improvements in cognitive function (executive function, memory) in adults with mild cognitive impairment
- Unlike direct GH, Tesamorelin preserves the natural GH feedback loop via somatostatin — no axis suppression
Storage & Reconstitution
Store lyophilized powder at -20°C. Reconstitute with sterile water or BAC water immediately before use. Recommended: add 2 mL BAC water to 10 mg vial → yields 5 mg/mL. CRITICAL: Inject immediately after reconstitution — do NOT store reconstituted solution. Do not freeze reconstituted solution.
Key Studies
Effects of Tesamorelin on Visceral Fat and Liver Fat in HIV-Infected Patients
Falutz J et al.
Tesamorelin reduced visceral adipose tissue by 15–18% over 26 weeks — the basis for FDA approval as Egrifta.
PubMed →Tesamorelin reduces visceral fat and liver fat in HIV-infected patients
Stanley TL et al.
Tesamorelin selectively reduced visceral fat while preserving subcutaneous fat with significant IGF-1 elevation.
PubMed →Tesamorelin improves cognitive function in older adults with mild cognitive impairment
Baker LD et al.
Tesamorelin improved executive function and memory in adults with mild cognitive impairment via IGF-1 signaling in the brain.
PubMed →Pharmacokinetics
Bioavailability indicates how much of the compound reaches systemic circulation. Peak plasma is when blood levels are highest. Half-life determines dosing frequency — compounds with short half-lives require more frequent dosing to maintain therapeutic levels.
The volume of distribution reflects how widely the compound distributes into tissues. A higher Vd means the compound concentrates in tissues rather than staying in plasma.
Receptor Binding Profile
Robust pulsatile GH release from pituitary somatotrophs
15–18% visceral fat reduction via GH/IGF-1 axis — FDA-approved mechanism
2–3× greater IGF-1 elevation vs Sermorelin; cognitive benefits via brain IGF-1 signaling
Side Effects & Adverse Events
- Injection site reactions (25%)
- Fluid retention
- Joint pain
- Glucose intolerance
- Carpal tunnel syndrome symptoms
- Glucose elevation (monitor in diabetes)
- Elevated IGF-1 (monitor levels)
Contraindications & Interactions
Synergistic Compounds
GHRH + GHRP dual-signal mechanism amplifies GH pulse for enhanced body composition effects.
Tesamorelin 1 mg + Ipamorelin 200 mcg, both SubQ, once daily.
View Compound →Tesamorelin targets visceral fat via GH/IGF-1 axis while AOD-9604 directly activates adipocyte lipolysis.
Tesamorelin 1 mg SubQ daily + AOD-9604 300 mcg SubQ fasted AM.
View Compound →Transparent Global Sourcing
Manufactured
Sourced through our manufacturing partner in China
Independent Testing
Analytical reports available from Janoshik Analytical
Batch Verification
Batch-specific COAs with online verification via janoshik.com
US Fulfillment
Orders fulfilled from the United States